A Revolution in Disease Treatment

Crosshair is leveraging a novel AI drug discovery platform to create an entirely new class of therapeutics to treat cancer, ageing and other diseases.

Find Out More

A Revolution in Disease Treatment

Crosshair is leveraging a novel AI drug discovery platform to create an entirely new class of therapeutics to treat cancer, ageing and other diseases.

Find Out More

Precision Targeting Platform

Our D-Chain Technology platform enables unrestricted access to the most difficult disease targets and represents an order-of-magnitude step-change in precision targeting compared to the latest immunotherapies. We utilize computational modeling to rapidly design our chain-like  therapeutics at low cost, and encode them for delivery in custom engineered gene therapy vectors.

The Ecosystem

The Ecosystem.

Intelligent Therapeutic design
‍
Precision Drug delivery
‍
Personalized Medicine

The Ecosystem.

Intelligent Therapeutic design

Precision Targeting

with D-Chain Technology

Almost 80% of disease targets have no drugs that act on them. Most of these targets are considered hard to drug or undruggable. As a result, these is a limited number of therapeutics available for cancer and other diseases of high unmet need. Our chain-like therapeutics are an entirely novel class of drugs, custom designed to eliminate the the most difficult disease targets. Unlike conventional therapies such as small molecule drugs, D-Chains do not require a binding pocket on the target protein, and in contrast to antibody-based therapies, D-Chains can easily reach intracellular targets, with superior specificity. D-Chain therapeutics can be designed in as little as 2 weeks, effectively eliminating the need for costly, time-consuming drug screens to identify a lead drug candidate. D-Chain structures are small, highly flexible and capable of utilizing a multitude of mechanisms to inhibit (or activate) targets, which means our technology has unmatched access to the hard-to-drug or undruggable space. Drug inhibition modalities utilized by our competitors are easily accessible to us, plus we can implement many modalities inaccessible to our competitors.

The Ecosystem.

Precision
Drug Delivery

Engineered AAVs

for customized precision drug delivery

In the absence of precision-guided delivery, drugs travel throughout the body - in addition to diseased cells, they can act on the patients’ healthy cells and tissues. This is a major problem that leads to high patient burden, suffering, clinical trial failure and even death.

At Crosshair, we are harnessing the adeno-associated virus (AAV) to deliver our peptides, encoding them as DNA, just as gene therapies are encoded. We then use our D-Chains to modify the surface of the AAV, which enables the AAV to reach a specific target with laser-guided precision. The AAV can then target specific cell receptors or tumor-associated antigens, present only on cancer cells.

This allows Crosshair to leverage our precision targeting platform at both levels - first, to reach only disease cells with the drug payload, and second to discriminate target versus non-targets once inside the cell. Both levels of precision combine to create a platform with unmatched ability to eliminate adverse off-targeting that often leads to side-effects experienced by patients

The Ecosystem.

Personalized Medicine

Custom Therapies

informed by Molecular Profiling

In the absence of precision-guided delivery, drugs travel throughout the body - in addition to diseased cells, they can act on the patients’ healthy cells and tissues. This is a major problem that leads to high patient burden, suffering, clinical trial failure and even death.

At Crosshair, we are harnessing the adeno-associated virus (AAV) to deliver our peptides, encoding them as DNA, just as gene therapies are encoded. We then use our D-Chains to modify the surface of the AAV, which enables the AAV to reach a specific target with laser-guided precision. The AAV can then target specific cell receptors or tumor-associated antigens, present only on cancer cells.

This allows Crosshair to leverage our precision targeting platform at both levels - first, to reach only disease cells with the drug payload, and second to discriminate target versus non-targets once inside the cell. Both levels of precision combine to create a platform with unmatched ability to eliminate adverse off-targeting that often leads to side-effects experienced by patients

Our Team & Advisors.

Michael Bruno, PhD

Co-Founder and CEO

Michael Bruno is a 20 year academia and industry veteran, having held postions at both Yale and Stanford University, specialising in novel drug discovery technologies, before moving into industry seven years ago.

Michael Snyder, PhD

Co-Founder and Science Advisor

Professor Snyder is Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine at Stanford University. He is a board member, advisor and co-founder of several biotech companies, including Personalis.

Michelle Arkin, PhD

Science Advisor

Professor Arkin is Chair of Pharmaceutical Chemistry at UC San Franscisco. She is a leader in the development of novel drug discovery technologies and has prior industry experience with Genentech.

Michele Marzola, MBA

Business Advisor

Michele Marzola is a serial entrepreneur in the life sciences and has led several biotech companies, including those developing novel therapies in oncology.

Typeform

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

We are eager to collaborate and partner to develop game-changing therapies.

Partner with us

LinkedIn

Contact

Email us

Twitter

Located

428 Oakmead Pkwy, Sunnyvale, CA 94085, USA.

© 2022 by Crosshair Therapeutics. All rights reserved.
Copyright   T&C   Privacy Policy